Syneron Medical Ltd. (NASDAQ:ELOS) shares saw an uptick in trading volume on Monday . 171,739 shares were traded during trading, an increase of 13% from the previous session’s volume of 152,467 shares.The stock last traded at $7.07 and had previously closed at $7.01.

Several research firms have issued reports on ELOS. Brean Capital reissued a “buy” rating and set a $13.00 target price on shares of Syneron Medical in a research note on Monday, August 8th. Leerink Swann cut Syneron Medical from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $9.40 to $7.80 in a research note on Friday, August 5th. Finally, Zacks Investment Research raised Syneron Medical from a “sell” rating to a “hold” rating in a research note on Monday, July 25th.

The firm’s 50 day moving average price is $7.23 and its 200 day moving average price is $7.18. The stock’s market capitalization is $245.16 million.

Syneron Medical (NASDAQ:ELOS) last posted its earnings results on Thursday, August 4th. The company reported $0.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.03. During the same period in the previous year, the company posted $0.07 EPS. The company earned $75 million during the quarter, compared to analysts’ expectations of $75.72 million. Syneron Medical’s quarterly revenue was up 2.0% compared to the same quarter last year. Equities analysts predict that Syneron Medical Ltd. will post $0.27 EPS for the current fiscal year.

An institutional investor recently bought a new position in Syneron Medical stock. Drill Craig A purchased a new position in Syneron Medical Ltd. (NASDAQ:ELOS) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 368,820 shares of the company’s stock, valued at approximately $2,844,000. Syneron Medical comprises 3.7% of Drill Craig A’s holdings, making the stock its 10th largest position. Drill Craig A owned approximately 1.01% of Syneron Medical at the end of the most recent quarter.

Syneron Medical Ltd. is engaged in manufacture, research, development, marketing and sales of advanced equipment for the aesthetic medical industry and systems for dermatologists, plastic surgeons and other qualified practitioners. The Company designs, develops and markets aesthetic medical products based on its various technologies, including Electro-Optical Synergy (ELOS) technology to provide aesthetic medical treatments.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.